Description
Chemical name: 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
Formula: C28H38N6O11S
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
SILDIGRA CT 7 CHEWABLE
Description: SILDIGRA CT 7 is a chewable tablet formulation of Sildenafil Citrate, designed for the treatment of erectile dysfunction (ED) in men. Each chewable tablet contains 100 mg of Sildenafil Citrate, providing a convenient and fast-acting option for improving erectile function. Manufactured by Dharam Distributors, SILDIGRA CT 7 offers a reliable solution for men seeking to enhance their sexual performance.
Indications: SILDIGRA CT 7 is indicated for the treatment of erectile dysfunction (ED), a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It helps improve erectile function by increasing blood flow to the penis during sexual stimulation.
Mechanism of Action: Sildenafil Citrate, the active ingredient in SILDIGRA CT 7, is a phosphodiesterase type 5 (PDE5) inhibitor. It works by inhibiting the PDE5 enzyme, which regulates blood flow in the penis. By blocking this enzyme, Sildenafil Citrate enhances the effects of nitric oxide, a natural chemical that relaxes the muscles in the penis and increases blood flow, facilitating the achievement and maintenance of an erection.
Dosage and Administration: The recommended dosage of SILDIGRA CT 7 is one 100 mg chewable tablet taken orally as needed, approximately 30 minutes to 1 hour before anticipated sexual activity. The tablet should be chewed thoroughly before swallowing. The maximum recommended dosing frequency is one tablet per day. It is important to follow the dosage instructions provided by a healthcare professional.
Precautions:
- SILDIGRA CT 7 should not be used in combination with medications containing nitrates or nitric oxide donors, as this may lead to a sudden and dangerous drop in blood pressure.
- Patients with a history of cardiovascular disease, liver or kidney impairment, or certain eye conditions should use SILDIGRA CT 7 with caution and under medical supervision.
- Alcohol consumption and grapefruit juice intake should be avoided while taking SILDIGRA CT 7, as they may increase the risk of side effects.
Adverse Reactions: Common adverse reactions associated with SILDIGRA CT 7 may include headache, flushing, indigestion, nasal congestion, dizziness, and visual disturbances. In rare cases, more serious side effects such as priapism (a prolonged and painful erection), sudden hearing loss, and severe allergic reactions may occur.
Storage: SILDIGRA CT 7 tablets should be stored at room temperature, away from moisture, heat, and direct sunlight. Keep the tablets in their original packaging and out of reach of children. Unused or expired tablets should be disposed of properly according to local regulations.
Disclaimer: The information provided here is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional regarding any questions or concerns you may have about your condition or treatment options.
Reviews
There are no reviews yet.